Press Releases

2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

December 22, 2016

Ironwood and Allergan Report Topline Phase IIb Data Supporting Further Investigation of Linaclotide Colonic Release-2 (CR2) for Abdominal Pain in Non-Constipation Subtypes of IBS

December 22, 2016

Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic Release-1 (CR1) in IBS-C

December 19, 2016

Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in Japan for the Treatment of Adults with IBS-C

November 13, 2016

Ironwood Highlights ZURAMPIC® (lesinurad) Phase III Extension Study Data at the American College of Rheumatology 2016 Annual Meeting

November 10, 2016

Ironwood Pharmaceuticals to Present at Stifel 2016 Healthcare Conference

November 3, 2016

Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update

November 1, 2016

Ironwood Pharmaceuticals to Present at Credit Suisse 25th Annual Healthcare Conference

October 25, 2016

Ironwood Highlights Breadth of Gout Research with Presentations at the American College of Rheumatology 2016 Annual Meeting

October 20, 2016

Ironwood Pharmaceuticals to Host Third Quarter 2016 Investor Update Call

October 3, 2016

Nine in Ten Physicians Agree Target Goal for Gout Is Imperative, Yet Half of Patients Fail to Reach It, New Survey Shows

October 3, 2016

Ironwood Announces U.S. Availability of ZURAMPIC® (lesinurad) 200 mg Tablets for Patients with Uncontrolled Gout

September 26, 2016

Ironwood Closes $150 Million Debt Refinancing

September 7, 2016

Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference

September 1, 2016

Ironwood Pharmaceuticals to Present at Wells Fargo 2016 Healthcare Conference

August 4, 2016

Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update

July 21, 2016

Ironwood Pharmaceuticals to Host Second Quarter 2016 Investor Update Call

June 9, 2016

Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review

June 6, 2016

Ironwood Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference

June 3, 2016

Ironwood Pharmaceuticals Closes U.S. Transaction with AstraZeneca for Lesinurad

June 1, 2016

Ironwood Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference

May 18, 2016

Ironwood Pharmaceuticals to Present at 2016 UBS Global Healthcare Conference

May 17, 2016

Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week® 2016

May 9, 2016

Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update

May 3, 2016

Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2016 Health Care Conference

April 26, 2016

Ironwood Pharmaceuticals Enters into U.S. Licensing Agreement with AstraZeneca for Lesinurad

April 25, 2016

Ironwood Pharmaceuticals to Host First Quarter 2016 Investor Update Call

April 7, 2016

Ironwood Pharmaceuticals Appoints Andrew Dreyfus to Board of Directors

April 5, 2016

Ironwood Pharmaceuticals Reports Top-Line Data from Exploratory Phase IIa Study of IW-9179 in Diabetic Gastroparesis

March 30, 2016

Ironwood Pharmaceuticals to Present Clinical and Preclinical Data on sGC Stimulators at Upcoming Scientific Conferences

March 23, 2016

Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease

March 9, 2016

Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference

March 1, 2016

Ironwood Pharmaceuticals to Present at Cowen and Company 36th Annual Health Care Conference

February 29, 2016

Video Alert: Updated 2016 Direct-to-Consumer Awareness Campaign Available for LINZESS® (linaclotide)

February 24, 2016

Ironwood Pharmaceuticals Announces Filing by Astellas of New Drug Application in Japan with Linaclotide for the Treatment of Adults with IBS-C

February 18, 2016

Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2015 Investor Update

February 18, 2016

Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701

February 17, 2016

Ironwood Pharmaceuticals to Present at 2016 RBC Capital Markets Global Healthcare Conference

February 4, 2016

Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2015 Investor Update Call

January 11, 2016

Ironwood Pharmaceuticals Details Strategy to Build Top-Performing Commercial Biotechnology Company

January 4, 2016

Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference